© 2018 by BioSight Ltd.

  • LinkedIn Social Icon

Pipeline

Biosight is developing innovative therapeutics for hematological malignancies and disorders.

‚Äč

Our lead product, BST-236 (INN aspacytarabine), is an innovative proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. BST-236is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging Phase 1/2a, which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard therapy. Additional clinical studies in additional hematological indications are planned to be initiated in 2020.

BIOSIGHT logo .png